7,632 results match your criteria Meningitis Meningococcal

[Recurrent meningococcal infection in a young woman witha mutation in the C8B gene].

Ugeskr Laeger 2022 Jun;184(23)

Pædiatrisk Afdeling, Sjællands Universitetshospital, Roskilde.

This is a case report of recurrent meningococcal infection in a young woman. She had no positive microbiological findings but was serologically diagnosed with the meningococcal antibody test. Investigation of the complement system showed no function of the terminal pathway. Read More

View Article and Full-Text PDF

Prevalence of serogroups in invasive meningococcal disease in China, 2010 - 2020: a systematic review and meta-analysis.

Hum Vaccin Immunother 2022 Jun 10:2071077. Epub 2022 Jun 10.

State Key Laboratory of Infectious Disease Prevention and Control, National Institute for Communicable disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.

Invasive meningococcal disease (IMD) caused by () continues to be a global public health concern. Understanding the prevalence of serogroups in IMD is critical for developing strategies for meningococcal vaccination. We used the keywords "cerebrospinal meningitis", "meningococcal", "'', "meningococcal meningitis", "serogroup'' and "China'' to search five databases, including PubMed, CNKI, CBM (Chinese BioMedical Literature Database), WanFang and VIP from 2010 to 2020. Read More

View Article and Full-Text PDF

A systematic review and meta-analysis on the antibiotic resistance of Neisseria meningitidis in the last 20 years in the world.

Indian J Med Microbiol 2022 May 30. Epub 2022 May 30.

Infectious Diseases Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran. Electronic address:

Background: Neisseria meningitidis is one of the most important causes of meningitis and pathogens-associated deaths in developing and developed countries. Effective anti-microbial agents are pivotal to treat and control N. meningitidis infections. Read More

View Article and Full-Text PDF

[Epidemiological and etiological analysis of two infantile cases of serogroup B epidemic cerebrospinal meningitis epidemics in Shandong Province, 2021].

Zhonghua Yu Fang Yi Xue Za Zhi 2022 May;56(5):668-672

Division of Expanded Immunization Program, Shandong Center for Disease Control and Prevention/Shandong Academy of Preventive Medicine; Academy of Preventive Medicine, Shandong University/Shandong Provincial Key Laboratory of Infectious Disease Control and Prevention, Jinan 250014, China.

Two cases of epidemic situation of serogroup B meningitis in infants in Shandong Province in 2021 were investigated. Samples of cases and their close contacts were collected for isolation, culture and identification of (). The isolates were subjected to multi-locus sequence typing, outer membrane protein and genotyping and drug sensitivity test. Read More

View Article and Full-Text PDF

[Research progress on immunogenicity evaluation of serogroup B meningococcal vaccine].

Zhonghua Yu Fang Yi Xue Za Zhi 2022 May;56(5):652-658

Institute for Communicable Disease Prevention and Control,Chinese Center for Disease Control and Prevention, Beijing 102206, China.

Epidemic cerebrospinal meningitis (meningococcal meningitis) is an acute respiratory infectious disease with high mortality and serious sequelae. Meningococcal vaccine is an effective measure to prevent and control meningococcal meningitis. At present, group B meningococcal meningitis has become the main prevalent serum group in the world, including China. Read More

View Article and Full-Text PDF

Pathogen- and Type-Specific Changes in Invasive Bacterial Disease Epidemiology during the First Year of the COVID-19 Pandemic in The Netherlands.

Microorganisms 2022 May 5;10(5). Epub 2022 May 5.

Department of Medical Microbiology and Infection Prevention, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.

COVID-19 control measures have resulted in a decline in invasive bacterial disease caused by (IMD), (IPD), and (Hi-D). These species comprise different serogroups and serotypes that impact transmissibility and virulence. We evaluated type- and pathogen-specific changes in invasive bacterial disease epidemiology in the Netherlands during the first year of the SARS-CoV-2 pandemic. Read More

View Article and Full-Text PDF

Long-term impact of invasive meningococcal disease in children: SEINE study protocol.

PLoS One 2022 26;17(5):e0268536. Epub 2022 May 26.

Centre Hospitalier Intercommunal, Clinical Research Center, Créteil, France.

Introduction: Invasive meningococcal disease (IMD) is still an important cause of mortality in children and survivors can have significant long-term disabling sequelae. There are few prospective studies looking at the long term neuropsychological and developmental consequences of IMD in surviving children, and the rate of sequelae may be underestimated. The SEINE study aims to have a more reliable estimate of the real rate of sequelae by assessing the long-term physical, neuropsychological, learning disorders and sensory sequelae of IMD in children and adolescents and by assessing the post-traumatic stress in parents. Read More

View Article and Full-Text PDF

Application of a Neisseria meningitidis antigen microarray to identify candidate vaccine proteins from a human Phase I clinical trial.

Vaccine 2022 Jun 21;40(28):3835-3842. Epub 2022 May 21.

Lydia Becker Institute of Immunology and Inflammation, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester M13 9PL, UK. Electronic address:

Meningococcal meningitis is a rare but serious condition affecting mainly children and young adults. Outer membrane vesicles (OMV) from Neisseria meningitidis have been used successfully as vaccines against the disease, although they only provide protection against a limited number of the many existing variants. There have been many attempts to identify suitable protein antigens for use in defined vaccines that provide broad protection against the disease, such as that leading to the development of the four component 4CMenB vaccine. Read More

View Article and Full-Text PDF

Structural characterization of a cross-protective natural chimera of factor H binding protein from meningococcal serogroup B strain NL096.

Comput Struct Biotechnol J 2022 18;20:2070-2081. Epub 2022 Apr 18.

GSK Vaccines srl, Via Fiorentina 1, Siena 53100, Italy.

Invasive meningococcal disease can cause fatal sepsis and meningitis and is a global health threat. Factor H binding protein (fHbp) is a protective antigen included in the two currently available vaccines against serogroup B meningococcus (MenB). FHbp is a remarkably variable surface-exposed meningococcal virulence factor with over 1300 different amino acid sequences identified so far. Read More

View Article and Full-Text PDF

Meningococcal Disease and Immunization Activities in Hajj and Umrah Pilgrimage: a review.

Infect Dis Ther 2022 May 19. Epub 2022 May 19.

College of Medicine, Al Faisal University, Riyadh, Saudi Arabia.

Invasive meningococcal disease (IMD) outbreaks associated with Hajj and Umrah pilgrimage events in the Kingdom of Saudi Arabia (KSA) are well recognized. Past outbreaks have been associated with substantial intercontinental spread of specific Neisseria meningitidis serogroups. The emergence of meningococcal serogroup W (MenW) was a global concern following the 2000/2001 Hajj outbreaks. Read More

View Article and Full-Text PDF

Meningococcal B vaccine effectiveness.

J Pediatr 2022 05;244:250-254

Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain.

View Article and Full-Text PDF

The Host-Pathogen Interactions and Epicellular Lifestyle of .

Front Cell Infect Microbiol 2022 22;12:862935. Epub 2022 Apr 22.

Marshall Centre for Infectious Diseases Research and Training, School of Biomedical Sciences, University of Western Australia, Perth, WA, Australia.

is a gram-negative diplococcus and a transient commensal of the human nasopharynx. It shares and competes for this niche with a number of other species including and . Unlike these other members of the genus, may become invasive, crossing the epithelium of the nasopharynx and entering the bloodstream, where it rapidly proliferates causing a syndrome known as Invasive Meningococcal Disease (IMD). Read More

View Article and Full-Text PDF

Response to a Serogroup B Meningococcal Disease Case Among Military Trainees.

Open Forum Infect Dis 2022 May 8;9(5):ofac162. Epub 2022 Apr 8.

Infectious Disease Service, Brooke Army Medical Center, Joint Base San Antonio, Texas, USA.

We describe the public health response to a military trainee who developed serogroup B meningococcal disease while sharing underwater breathing equipment. Despite high transmission risk, with rapid isolation and postexposure prophylaxis administration, there were no secondary cases. This case supports carefully weighing serogroup B meningococcal vaccination in high-risk settings. Read More

View Article and Full-Text PDF

A database study of clinical and economic burden of invasive meningococcal disease in France.

PLoS One 2022 29;17(4):e0267786. Epub 2022 Apr 29.

Pfizer France, Paris, France.

Objective: Invasive meningococcal disease (IMD) is life-threatening and associated with substantial morbidity and mortality. The study aimed to examine the clinical characteristics and hospital-based healthcare resource use and related costs following IMD diagnosis in France.

Methods: Patients admitted to hospitals due to IMD between 2014 and 2016 were selected from the French hospital discharge database (PMSI). Read More

View Article and Full-Text PDF

One-Year Sequelae and Quality of Life in Adults with Meningococcal Meningitis: Lessons from the COMBAT Multicentre Prospective Study.

Adv Ther 2022 06 28;39(6):3031-3041. Epub 2022 Apr 28.

Institute Pasteur, 25-28 Rue du Dr Roux, 75015, Paris, France.

Introduction: COMBAT is a prospective, multicentre cohort study that enrolled consecutive adults with community-acquired bacterial meningitis (CABM) in 69 participating centres in France between February 2013 and July 2015 and followed them for 1 year.

Methods: Patients aged at least 18 years old, hospitalised with CABM were followed during their hospitalisation and then contacted by phone 12 months after enrolment. Here we present the prevalence of sequelae at 12 months in a subgroup of patients with meningococcal meningitis. Read More

View Article and Full-Text PDF

Efficacy and Effectiveness of the Meningococcal Conjugate Group A Vaccine MenAfriVac in Preventing Recurrent Meningitis Epidemics in Sub-Saharan Africa.

Vaccines (Basel) 2022 Apr 14;10(4). Epub 2022 Apr 14.

Department of Molecular and Developmental Medicine, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy.

For more than a century, epidemic meningococcal disease mainly caused by serogroup A has been an important public health problem in sub-Saharan Africa. To address this problem, an affordable meningococcal serogroup A conjugate vaccine, MenAfriVac, was developed specifically for populations in the African meningitis belt countries. MenAfriVac was licensed based on safety and immunogenicity data for a population aged 1-29 years. Read More

View Article and Full-Text PDF

The Collateral Effect of COVID-19 on the Epidemiology of Airborne/Droplet-Transmitted Notifiable Infectious Diseases in Taiwan.

Antibiotics (Basel) 2022 Apr 3;11(4). Epub 2022 Apr 3.

Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying, Tainan 73657, Taiwan.

This study was conducted to compare the number of cases of airborne/droplet-transmitted notifiable infectious disease (NID) between the pandemic period (defined as from January 2020 to December 2021) and the pre-pandemic period (defined as the period from January 2018 to December 2019). The annual case numbers of airborne/droplet-transmitted NIDs from 2018 to 2021 were collected for comparison. Fourteen airborne/droplet-transmitted NIDs including measles, rubella, pertussis, influenza with severe complications, invasive pneumococcal diseases (IPD), Q fever, mumps, meningococcal meningitis, varicella, legionellosis, invasive Haemophilus influenzae type b infection, hantavirus syndrome, TB, and multidrug-resistant TB (MDRTB), were included for the analysis. Read More

View Article and Full-Text PDF

Availability of polyamines affects virulence and survival of Neisseria meningitidis.

J Microbiol 2022 Jun 18;60(6):640-648. Epub 2022 Apr 18.

Symbiosis School of Biological Sciences, Symbiosis International (Deemed University) Lavale, Pune, 412115, India.

Neisseria meningitidis is a Gram-negative human-restricted pathogen that asymptomatically resides in the human respiratory tract. Meningococcal meningitis and sepsis both are caused by N. meningitidis. Read More

View Article and Full-Text PDF

Sequelae at Hospital Discharge in 61 Children With Invasive Meningococcal Disease, Chile, 2009-2019.

Pediatr Infect Dis J 2022 Apr 13. Epub 2022 Apr 13.

Department of Pediatrics, Faculty of Medicine, Universidad de Chile, Santiago, Chile.

Background: Invasive meningococcal disease (IMD) is an unpredictable and severe infection caused by Neisseria meningitidis. Its case fatality rate could vary from 9.7% to 26% and up to 36% of survivors may experience long-term sequelae, representing a challenge for public health. Read More

View Article and Full-Text PDF

Waterhouse-Friderichsen Syndrome with Bilateral Adrenal Hemorrhage Associated with Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia in an Adult Patient with History of Intravenous Drug Use.

Thomas Kalinoski

Am J Case Rep 2022 Apr 14;23:e936096. Epub 2022 Apr 14.

Department of Internal Medicine, Olive View - UCLA Medical Center, Sylmar, CA, USA.

BACKGROUND Waterhouse-Friderichsen syndrome, also known as acute adrenal insufficiency due to adrenal gland hemorrhage, is an uncommon and frequently fatal condition classically presenting with fever, shock, rash, and coagulopathy. Although most often associated with Meningococcemia, many other etiologies have been implicated, including reports of Staphylococcus aureus infection on autopsy examinations. This report details an adult intravenous drug user with adrenal hemorrhage associated with methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. Read More

View Article and Full-Text PDF

Meningococcal Disease in Pediatric Age: A Focus on Epidemiology and Prevention.

Int J Environ Res Public Health 2022 03 29;19(7). Epub 2022 Mar 29.

Pediatric Highly Intensive Care Unit, IRCCS Ca' Granda Foundation, Policlinico Hospital, 20122 Milan, Italy.

Meningococcal disease is caused by ; 13 serogroups have been identified and differentiated from each other through their capsular polysaccharide. Serotypes A, B, C, W, X, and Y are responsible for nearly all infections worldwide. The most common clinical manifestations are meningitis and invasive meningococcal disease, both characterized by high mortality and long-term sequelae. Read More

View Article and Full-Text PDF

Meningococcal Vaccination:: An Update on Meningococcal Vaccine Recommendations for the Primary Care Physician.

Dela J Public Health 2022 Mar 29;8(1):76-78. Epub 2022 Mar 29.

Director, Pediatric Infectious Disease; Director, Quality Assurance and Performance Improvement, ChristianaCare; Co-Chair, Immunization Coalition of Delaware.

Neisseria meningitidis is an aerobic, gram-negative, diplococcus bacterium that is a leading cause of meningitis and sepsis in the United States. Particularly at-risk groups include those with complement deficiencies, people using complement inhibitors, individuals with anatomic or functional asplenia, patients with HIV infection and travelers to endemic countries. There are currently three quadrivalent meningococcal vaccines (Serogroups A, C, W, Y) and two recombinant serogroup B vaccines available for use in the United States, and recommendations for vaccine use have changed rapidly in the past 10-15 years. Read More

View Article and Full-Text PDF

Impact of COVID-19 pandemic on vaccination against meningococcal C infection in Brazil.

Vaccine X 2022 Apr 19;10:100156. Epub 2022 Mar 19.

Department of Maternal and Child Nursing and Public Health, School of Nursing, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.

Objective: Analyzing the impact of COVID-19 pandemic on meningococcal C conjugate vaccination in Brazil.

Methods: Ecological study, based on interrupted time series, carried out with data collected through the Information System of the National Immunization Program (IS-NIP). Collected data refer to the number of meningococcal C conjugate vaccine doses administered from March 2019 to December 2020. Read More

View Article and Full-Text PDF

Risk Factors for Contracting Invasive Meningococcal Disease and Related Mortality: A Systematic Literature Review and Meta-analysis.

Int J Infect Dis 2022 Jun 23;119:1-9. Epub 2022 Mar 23.

Sanofi Pasteur, Global Medical Affairs, Dubai, UAE.

Objectives: To describe risk factors (RFs) and quantify their effects in invasive meningococcal disease (IMD) and associated mortality across all age groups based on the available published literature.

Methods: A systematic literature review (SLR) was conducted via MEDLINE® and Embase. Study selection, data extraction, and quality assessment were performed by two independent reviewers. Read More

View Article and Full-Text PDF

Enhancing meningococcal genomic surveillance in the meningitis belt using high-resolution culture-free whole genome sequencing.

J Infect Dis 2022 Mar 24. Epub 2022 Mar 24.

Centers for Disease Control and Prevention, Atlanta, USA.

Rollout of meningococcal serogroup A conjugate vaccine in Africa started in 2010, aiming to eliminate meningitis outbreaks, in meningitis belt countries. Since then, studies have been conducted, primarily using isolates, to assess the vaccine impact on the distribution of meningococcal strains in the region. Here, we implemented an innovative, culture-free whole genome sequencing approach on almost 400 clinical specimens collected between 2017-2019 from meningococcal meningitis cases in 6 African countries. Read More

View Article and Full-Text PDF

Disease transmission and mass gatherings: a case study on meningococcal infection during Hajj.

BMC Infect Dis 2022 Mar 22;22(1):275. Epub 2022 Mar 22.

York University, Toronto, Canada.

Background: Mass gatherings can not only trigger major outbreaks on-site but also facilitate global spread of infectious pathogens. Hajj is one of the largest mass gathering events worldwide where over two million pilgrims from all over the world gather annually creating intense congestion.

Methods: We developed a meta-population model to represent the transmission dynamics of Neisseria meningitidis and the impact of Hajj pilgrimage on the risk of invasive meningococcal disease (IMD) for pilgrims population, local population at the Hajj site and country of origin of Hajj pilgrims. Read More

View Article and Full-Text PDF

Epidemiology and treatment of sepsis at a public pediatric emergency department.

Einstein (Sao Paulo) 2022 7;20:eAO6131. Epub 2022 Mar 7.

Faculdade Israelita de Ciências da Saúde Albert Einstein, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.

Objective: To describe the clinical characteristics and treatment of children with sepsis, severe sepsis, and septic shock at a pediatric emergency department of a public hospital.

Methods: A retrospective, observational study. The medical records of patients included in the hospital Pediatric Sepsis Protocol and patients with discharge ICD-10 A41. Read More

View Article and Full-Text PDF

Prevalence and significance of anaemia in childhood bacterial meningitis: a secondary analysis of prospectively collected data from clinical trials in Finland, Latin America and Angola.

BMJ Open 2022 03 14;12(3):e057285. Epub 2022 Mar 14.

Faculty of Medicine, University of Helsinki, Helsinki, Finland.

Objectives: To describe the prevalence and severity of anaemia and to examine its associations with outcome in children with bacterial meningitis (BM).

Design: Secondary analysis of descriptive data from five randomised BM treatment trials.

Setting: Hospitals in Finland, Latin America and Angola. Read More

View Article and Full-Text PDF

Equity in vaccination policies to overcome social deprivation as a risk factor for invasive meningococcal disease.

Expert Rev Vaccines 2022 05 29;21(5):659-674. Epub 2022 Mar 29.

Global Medical Affairs Neisseria, GSK, Rueil-Malmaison, France.

Introduction: Social deprivation is associated with poorer healthcare access. Vaccination is among the most effective public health interventions and achieving equity in vaccination access is vitally important. However, vaccines are often reimbursed by public funds only when recommended in national immunization programs (NIPs), which can increase inequity between high and low socioeconomic groups. Read More

View Article and Full-Text PDF

Genomic Insights on Variation Underlying Capsule Expression in Meningococcal Carriage Isolates From University Students, United States, 2015-2016.

Front Microbiol 2022 17;13:815044. Epub 2022 Feb 17.

Meningitis and Vaccine Preventable Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Coordinating Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States.

In January and February 2015, serogroup B (NmB) outbreaks occurred at two universities in the United States, and mass vaccination campaigns using MenB vaccines were initiated as part of a public health response. Meningococcal carriage evaluations were conducted concurrently with vaccination campaigns at these two universities and at a third university, where no NmB outbreak occurred. Meningococcal isolates ( = 1,514) obtained from these evaluations were characterized for capsule biosynthesis by whole-genome sequencing (WGS). Read More

View Article and Full-Text PDF
February 2022